Surgical implantation of a polymer prosthetic mitral or aortic valve

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, exploratory, single-center study that will enroll 10 adults requiring either mitral or aortic valve replacement, with five patients in each valve group. Participants will undergo surgical implantation of an investigational polymer prosthetic valve and attend follow-up visits at 30 days, 3–6 months, and 12 months for clinical event monitoring and echocardiography. The primary endpoint is the rate of valve-related complications at 12 months, including thromboembolism, valve thrombosis, severe perivalvular leak, severe bleeding, and endocarditis. Secondary endpoints include immediate device success, valve hemodynamics, comprehensive safety events (e.g., mortality, reoperation, valve extraction, structural or non-structural dysfunction), NYHA class, and KCCQ quality-of-life measures.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adults requiring surgical replacement of either mitral or aortic valve
* Capable of undergoing cardiopulmonary bypass
* Able to tolerate anticoagulation therapy
* Able to understand study purpose, willing to provide informed consent and comply with follow-up

Exclusion Criteria:

1. History of previous cardiac valve surgery or percutaneous valve replacement, including surgical aortic or mitral valve replacement (excluding Percutaneous Balloon Mitral Valvuloplasty \[PBMV\], which is permitted).
2. Requirement for urgent or emergency cardiac surgery.
3. Planned concurrent aortic valve surgery or combined valve procedure (e.g., simultaneous aortic and mitral valve surgery).
4. Scheduled coronary artery bypass graft (CABG) during the same admission.
5. Anticipated need for additional non-valve cardiac surgery within 12 months.
6. Active systemic infection, including pneumonia or infective endocarditis.
7. Intracardiac thrombus detected on echocardiography or imaging.
8. Stroke or transient ischemic attack within the prior 3 months.
9. Myocardial infarction, unstable coronary syndrome, or coronary revascularization within the prior 3 months.
10. Severe comorbidities with expected life expectancy \<12 months, including Child-Pugh C liver disease, end-stage malignancy, or advanced pulmonary disease.
11. Participation in another interventional clinical trial involving investigational devices or drugs.
12. Anatomical risk factors such as ascending aortic aneurysm (≥50 mm), bicuspid aortic valve with ascending aorta ≥45 mm, or other high-risk features identified on imaging.
13. Left ventricular ejection fraction (LVEF) ≤35%, indicating severe systolic dysfunction.
14. Severe renal insufficiency, e.g., estimated GFR \<30 mL/min/1.73 m² or requirement for chronic dialysis.
15. Coagulopathy or active bleeding disorders, e.g., INR \>1.5 without anticoagulation therapy.
16. Hematologic abnormalities: hematocrit \<30%, hemoglobin \<100 g/L, platelet count \<100 × 10⁹/L, or WBC \<4 × 10⁹/L or \>10 × 10⁹/L.
17. History of substance abuse, chronic alcoholism, or significant psychiatric illness impairing study compliance.
18. Preoperative or intraoperative anatomical unsuitability of the valve apparatus or cardiac structure.
19. Known allergy or hypersensitivity to polyurethane, polyester, or sulfonate-based biomaterials used in the valve prosthesis.
20. Withdrawal from the study after valve implantation (such participants are not allowed to re-enroll).

Where it's running

• Department of Cardiovascular Surgery, Zhongshan Hospital, Fudan University
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Study coordinator: Lai Wei, MD
• Email: wei.lai@zs-hospital.sh.cn
• Phone: 021-51371990

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Abbott Cephea registry for mitral valve disease

  Collects clinical information on adults with symptomatic mitral valve disease to see how correcting the valve with the Cephea system affects outcomes for patients who might be candidates for transcatheter mitral valve replacement.

  Recruiting at 24 sites Abbott Medical Devices · Birmingham, Alabama and 23 other locations · NCT07069673

• Identifying sex-specific biological markers in valvular heart disease

  This study is testing if special heart scans can help find different biological markers for men and women with aortic valve disease to improve treatment and recovery after surgery.

  Recruiting The Cleveland Clinic · Cleveland, Ohio · NCT06780241

• MITRAL II Pivotal: Transcatheter mitral valve replacement for severe mitral annular calcification

  This trial tests whether placing an Edwards SAPIEN transcatheter valve through a transseptal approach helps high-surgical-risk adults with severe mitral annular calcification and symptomatic mitral valve dysfunction.

  Recruiting at 14 sites Mayo Clinic · Gilbert, Arizona and 16 other locations · NCT04408430

• DELINEATE-Prospective: AI-assisted echocardiogram analysis for valve disease

  This project will test whether an AI system can automatically analyze echocardiograms to help doctors detect valve problems in adults who get heart ultrasounds.

  Recruiting Columbia University · New York, New York · NCT07197736

• Transfemoral VitaFlow Liberty treatment for pure aortic regurgitation

  This trial will test whether replacing the aortic valve through the leg with the VitaFlow Liberty valve plus usual medical care helps people aged 60 and older with moderate-to-severe or worse isolated aortic regurgitation.

  Recruiting at 4 sites Phase 4 Ruijin Hospital · Shanghai, Shanghai Municipality and 3 other locations · NCT06818084

• Left atrial shunt to help after mitral valve surgery

  This study tests whether making a small opening between the left and right atria during mitral valve repair can relieve high left atrial pressure for adults with primary mitral regurgitation.

  Recruiting Ottawa Heart Institute Research Corporation · Ottawa, Ontario · NCT06547788

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.